Dogwood Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Dogwood Therapeutics, Inc. (DWTX) reported Increase (Decrease) in Accrued Liabilities of $632.22 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-08.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2024-11-08
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2024-09-30 was $596.54K.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2024-06-30 was -$91.01K.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2024-03-31 was $126.69K.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2023-12-31 was -$35.14K.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$223.46K.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$451.66K, a 405.65% decline from fiscal 2021.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2021 was $147.77K, a 80.92% decline from fiscal 2020.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2020 was $774.50K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2024-09-30 | $596.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $505.53K derived: sum of 2 quarters · filed 2024-11-08 | $632.22K 10-Q · filed 2024-11-08 | $597.08K derived: sum of 4 quarters · filed 2024-11-08 |
| 2024-06-30 | -$91.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $35.68K 10-Q · filed 2024-08-09 | $539.00 derived: sum of 3 quarters · filed 2024-08-09 | -$23.41K derived: sum of 4 quarters · filed 2024-11-08 |
| 2024-03-31 | $126.69K 10-Q · filed 2024-05-10 | $91.55K derived: sum of 2 quarters · filed 2024-05-10 | $67.60K derived: sum of 3 quarters · filed 2024-11-08 | -$40.87K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-12-31 | -$35.14K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-08 | -$59.09K derived: sum of 2 quarters · filed 2024-11-08 | -$167.56K derived: sum of 3 quarters · filed 2024-11-08 | -$223.46K 10-K/A · filed 2024-03-08 |
| 2023-09-30 | -$23.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$132.42K derived: sum of 2 quarters · filed 2024-11-08 | -$188.32K 10-Q · filed 2024-11-08 | -$622.95K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | -$108.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$164.37K 10-Q · filed 2024-08-09 | -$599.00K derived: sum of 3 quarters · filed 2024-08-09 | -$926.47K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$55.90K 10-Q · filed 2024-05-10 | -$490.53K derived: sum of 2 quarters · filed 2024-05-10 | -$818.00K derived: sum of 3 quarters · filed 2024-05-10 | -$1.13M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$434.63K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-08 | -$762.10K derived: sum of 2 quarters · filed 2024-03-08 | -$1.08M derived: sum of 3 quarters · filed 2024-03-08 | -$451.66K 10-K/A · filed 2024-03-08 |
| 2022-09-30 | -$327.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$641.78K derived: sum of 2 quarters · filed 2023-11-13 | -$17.03K 10-Q · filed 2023-11-13 | $161.44K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$314.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $310.43K 10-Q · filed 2023-08-11 | $488.90K derived: sum of 3 quarters · filed 2023-08-11 | $588.53K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $624.75K 10-Q · filed 2023-05-12 | $803.22K derived: sum of 2 quarters · filed 2023-05-12 | $902.84K derived: sum of 3 quarters · filed 2023-05-12 | $993.87K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $178.47K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $278.09K derived: sum of 2 quarters · filed 2023-03-14 | $369.13K derived: sum of 3 quarters · filed 2023-03-14 | $147.77K 10-K · filed 2023-03-14 |
| 2021-09-30 | $99.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $190.66K derived: sum of 2 quarters · filed 2022-11-14 | -$30.70K 10-Q · filed 2022-11-14 | $563.67K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $91.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$130.32K 10-Q · filed 2022-08-12 | $464.05K derived: sum of 3 quarters · filed 2022-08-12 | $533.80K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$221.35K 10-Q · filed 2022-05-13 | $373.01K derived: sum of 2 quarters · filed 2022-05-13 | $442.77K derived: sum of 3 quarters · filed 2022-05-13 | $471.30K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $594.37K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $664.12K derived: sum of 2 quarters · filed 2022-03-18 | $692.66K derived: sum of 3 quarters · filed 2022-03-18 | $774.50K 10-K · filed 2022-03-18 |
| 2020-09-30 | $69.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $98.29K derived: sum of 2 quarters · filed 2021-11-12 | $180.13K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $28.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $110.37K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $81.84K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |